



Citi Pharma Limited

PUBLIC ANNOUNCEMENT

Citi Pharma Limited and Mersi Farma (**Indonesia Based Leading Pharmaceutical Company**) Forge Strategic Partnership to Advance API Manufacturing and Expand Nutraceutical Market in Indonesia.

Citi Pharma Limited is proud to announce the signing of a **Memorandum of Understanding (MOU)** with Mersi Farma, marking a transformative collaboration to establish **Active Pharmaceutical Ingredient (API)** manufacturing facilities and expand nutraceutical product accessibility in Indonesia.

Key Provisions of the Partnership

1. Development of Advanced API Manufacturing Facilities

- **Paracetamol API Plant:**

A state-of-the-art facility with an annual production capacity of **10,000 metric tons per annum**.

- **Amoxicillin API Plant:**

A high-capacity plant with an annual production capacity of **1,800 metric tons per annum**.

These facilities will meet **Pharmaceutical Inspection Co-operation Scheme (PIC/S)** compliance standards, ensuring the highest quality production processes. The Paracetamol and Amoxicillin plants will be the **first large-scale API manufacturing facilities in Indonesia**, significantly reducing the country's dependence on imported APIs. This strategic initiative aims to bolster local production capacity, enhance self-reliance and contribute to Indonesia's healthcare infrastructure.

2. Joint Investment and Expertise Deployment

- **Citi Pharma Limited** will provide substantial **capital investment** and integrate **state-of-the-art technology** to establish world-class production capabilities.

- **Mersi Farma** will co-invest and utilize its extensive **operational network** within Indonesia to oversee operations and optimize market distribution for APIs.

3. Nutraceutical Market Penetration in Indonesia

- **Citi Pharma Limited** will introduce its premium nutraceutical product range, catering to the growing demand for health and wellness solutions.

- **Mersi Farma** will manage the **marketing, sales and distribution** of these products through its robust and well-established local distribution framework.



588 - Q, Johar Town, Lahore - Pakistan




3KM. Head Balloki Road, Phool Nagar, District Kasur - Pakistan




Head Office : +92. 42. 35316587 - 90 | Factory : +92. 49. 4510189, +92. 49. 4513392



www.citipharma.com.pk





Citi Pharma Limited

Strategic Implications

This partnership is a cornerstone of shared efforts to:

- **Drive innovation** in the pharmaceutical and nutraceutical sectors.
- **Enhance regional healthcare accessibility** through localized and high-quality API manufacturing.
- **Promote economic sustainability** by reducing Indonesia's reliance on API imports and fostering local industrial growth.

With the first bulk API manufacturing plant in Indonesia, this collaboration represents a pivotal shift toward self-sufficiency and technological advancement in the country's healthcare landscape.

Looking Ahead


Citi Pharma Limited and Mersi Farma are dedicated to making this partnership a model of excellence in pharmaceutical production and distribution. As this collaboration unfolds, further updates on milestones and achievements will be shared.



Company Secretary

Citi Pharma Limited – Care to Cure

Dated: December 03, 2024



588 - Q, Johar Town, Lahore - Pakisatn



3KM. Head Balloki Road, Phool Nagar, District Kasur - Pakistan



Head Office : +92. 42. 35316587 - 90 | Factory : +92. 49. 4510189, +92. 49. 4513392



www.citipharma.com.pk